| 朱海鹏,高志良,谭德明,刘水平.酸枣仁汤辅助治疗慢性重型肝炎的临床观察[J].,2007,(4):303-305 |
| 酸枣仁汤辅助治疗慢性重型肝炎的临床观察 |
| Clinical Observation on Auxiliary Treatment with Suanzaoren Decoction for Chronic Severe Hepatitis |
| |
| DOI： |
| 中文关键词: 酸枣仁汤 慢性重型肝炎 睡眠 |
| 英文关键词:Suanzaoren Decoction chronic severe hepatitis sleep |
| 基金项目: |
|
| Hits: 1292 |
| Download times: 1 |
| 中文摘要: |
| 目的研究酸枣仁汤辅助治疗慢性重型肝炎的疗效及安全性。方法将符合重型肝炎诊断标准的60例患者随机分为治疗组和对照组,每组各30例。对照组采用对症支持、抗感染、人工肝血浆置换等综合治疗,治疗组在此治疗基础上,加用酸枣仁汤口服治疗2周,观察两组患者睡眠情况,检测治疗前后血清总胆红素(TBIL)、凝血酶原活动度(PTA)、肿瘤坏死因子-α(TNF-α)和白细胞介素-1(IL-1)等指标,并观察药物的不良反应。结果酸枣仁汤治疗组的睡眠状况有显著改善,治疗后TBIL、TNF-α和IL-1血清浓度较治疗前明显降低。治疗组好转率66.7%(20/30例),显著高于对照组的40.0%(12/30例)。结论酸枣仁汤可以改善慢性重型肝炎患者的睡眠状态,减轻炎症细胞因子对肝细胞的损害。且无明显的不良反应。 |
| 英文摘要: |
| Objective To investigate the curative effect and safety of auxiliary treatment with Suanzaoren Decoction (SZRD) on patients with chronic severe hepatitis (CSH). Methods Sixty patients, with the diagnosis in accordance with the diagnostic criterion of CSH, were assigned to the treated group and the control group, 30 in each group. Patients in the control group were treated with comprehensive therapy including symptomatic supportive treatment, anti-infective therapy and artificial liver plasmapheresis etc., while those in the treated group were orally taken SZRD additionally. Patients’ condition of sleeping and changes of total bilirubin (TBIL), prothrombin activity (PTA), tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) were observed before and after treatment, and the adverse reactions were observed as well. Results The sleeping status were significantly improved in the treated group after treatment, and the serum levels of TBIL, TNF-α and IL-1 were significantly decreased. The improvement rate was 66.7%(20/30) and significantly higher than that (40.0%, 12/30) in the control group. Conclusion SZRD can significantly improve the sleeping status of CSH patients, alleviate the hepato-cellular injury by inflammatory cytokines and without obvious adverse reaction. |
| View Full Text View/Add Comment Download reader |
|
|
|
